GSK scores major trial win with potential multiple myeloma blockbusterGlaxoSmithKline may have scored a major cancer trial win after its belantamab mafodotin hit targets in the pivotal Share XGSK scores major trial win with potential multiple myeloma blockbusterhttps://pharmaphorum.com/news/gsk-scores-major-trial-win-with-potential-multiple-myeloma-blockbuster/
Smarter thinking about pharmaceutical marketingRobb DeFilippis, from end-to-end global creative production and sourcing partner Tag, discusses how a more effective multichannel pharma Share XSmarter thinking about pharmaceutical marketinghttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/tag-pharmaceutical-marketing-production/
Roche’s CMO Horning to retire, Lilly’s high-flyer Garraway steps inRoche’s influential chief medical officer Sandra Horning is to retire at the end of the year, the company Share XRoche’s CMO Horning to retire, Lilly’s high-flyer Garraway steps inhttps://pharmaphorum.com/news/roches-cmo-horning-to-retire/
AZ’s immunotherapy combo misses the mark in untreated lung cancerAstraZeneca’s immunotherapy combination has missed the mark in certain patients with untreated lung cancer, failing to improve survival Share XAZ’s immunotherapy combo misses the mark in untreated lung cancerhttps://pharmaphorum.com/news/azs-immunotherapy-combo-misses-the-mark-in-untreated-lung-cancer/
NICE’s track record in cancer drugs: the impact of the CDF and interim fundingLeela Barham looks back to before the Cancer Drugs Fund and how recommendations have changed through CDF 1.0 Share XNICE’s track record in cancer drugs: the impact of the CDF and interim fundinghttps://pharmaphorum.com/views-and-analysis/nices-track-record-in-cancer-drugs-the-impact-of-the-cdf-and-interim-funding/
Getting patients round the virtual tableIf pharma wants to be truly patient-centric, it needs to be talking to patients. This may seem obvious, Share XGetting patients round the virtual tablehttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/impetus-digital-patient-centric-engagement/
Celgene scores regulatory win ahead of BMS mergerCelgene has scored a major regulatory win ahead of its proposed merger with Bristol-Myers Squibb, with the FDA Share XCelgene scores regulatory win ahead of BMS mergerhttps://pharmaphorum.com/news/celgene-scores-regulatory-win-ahead-of-bms-merger/
FDA approves Roche’s “tumour agnostic” drug RozlytrekThe FDA has approved Roche’s Rozlytrek (entrectinib), a so-called “tumour agnostic” drug that is approved to key into certain mutations in Share XFDA approves Roche’s “tumour agnostic” drug Rozlytrekhttps://pharmaphorum.com/news/fda-approves-roches-tumour-agnostic-drug-rozlytrek/
2nd RNA Targeted Drug Discovery SummitAt a time when the previously untapped drug discovery opportunity promised within RNA opens up, the 2nd RNA- Targeted Drug Share X2nd RNA Targeted Drug Discovery Summithttps://pharmaphorum.com/events/2nd-rna-targeted-drug-discovery-summit/
